SEC Form SC 13D/A filed by Acutus Medical, Inc. (Amendment)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)

(Amendment No. 2)*

Acutus Medical, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

005111109

(CUSIP Number)

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 19, 2021

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 13 Pages)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

(1) Comprised of 3,438,589 shares of common stock and 402,998 shares of common stock underlying warrants held by Deerfield Private Design Fund III, L.P.

SCHEDULE 13D

(2) Comprised of 3,438,589 shares of common stock and 402,998 shares of common stock underlying warrants.

SCHEDULE 13D

(3) Comprised of 1,974,638 shares of common stock and 31,116 shares of common stock underlying warrants held by Deerfield Partners, L.P.

SCHEDULE 13D

(4) Comprised of 1,974,638 shares of common stock and 31,116 shares of common stock underlying warrants.

SCHEDULE 13D

(5) Comprised of (i) an aggregate of 5,413,227 shares of common stock and 434,114 shares of common stock underlying warrants held by Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. and (ii) 5,238 shares of common stock underlying stock options held by Andrew ElBardissi which are exercisable or will become exercisable within 60 days, which options are held for the benefit and at the direction of Deerfield Management Company, L.P.

SCHEDULE 13D

(6) Comprised of (i) an aggregate of 5,413,227 shares of common stock and 434,114 shares of common stock underlying warrants held by Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. and (ii) 5,238 shares of common stock underlying stock options held by Andrew ElBardissi which are exercisable or will become exercisable within 60 days, which options are held for the benefit and at the direction of Deerfield Management Company, L.P.

This Amendment No. 2 (this “Amendment”) to Schedule 13D amends the Schedule 13D filed by (i) Deerfield Mgmt III, L.P. (“Deerfield Mgmt III”), (ii) Deerfield Private Design Fund III, L.P. (“Deerfield Private Design Fund III”), (iii) Deerfield Mgmt, L.P. (“Deerfield Mgmt”), (iv) Deerfield Partners, L.P. (“Deerfield Partners”), (v) Deerfield Management Company, L.P. (“Deerfield Management”) and (vi) James E. Flynn, a natural person (“Flynn” and collectively with Deerfield Mgmt III, Deerfield Private Design Fund III, Deerfield Mgmt, Deerfield Partners and Deerfield Management, the “Reporting Persons”), as amended by Amendment No. 1 thereto (as previously amended, the “Schedule 13D”), with respect to the common stock of Acutus Medical, Inc. Deerfield Private Design Fund III and Deerfield Partners are collectively referred to herein as the “Funds”). Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to them in the Schedule 13D.

On July 19, 2021, Deerfield Private Design Fund III and Deerfield Partners, purchased 680,592 and 390,836 shares of Common Stock (collectively, the “2021 Public Offering Shares”), respectively, at a price of $14.00 per share, or aggregate purchase prices of $9,528,288 and $5,471,704, respectively. Each Fund utilized available cash assets to acquire its 2021 Public Offering Shares.

Item 4 of the Schedule 13D is hereby amended to add the following:

Each Fund acquired its 2021 Public Offering Shares for investment purposes in a public offering conducted by the Company (the “2021 Public Offering”). The Reporting Persons and the Company are in the process of finalizing the Series A Certificate of Designation and an exchange agreement consistent with the terms of the Letter Agreement. In connection with, and pursuant to, such exchange agreement, the Reporting Persons expect to amend each Warrant held by a Fund in a manner that would restrict the exercise of such securities to the extent that, upon such exercise, the number of shares of the Company’s Common Stock then beneficially owned by the holder, its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group,” would exceed 4.9% of the total number of shares of the Company’s Common Stock then outstanding.

Items 5(a), 5(b) and 5(c) of the Schedule 13D are hereby amended and restated in their entirety to read as follows:

(a)        

(b)       

Flynn is the managing member of the general partner of each of Deerfield Mgmt, Deerfield Mgmt III and Deerfield Management.   Deerfield Mgmt III is the general partner of Deerfield Private Design Fund IIII and Deerfield Mgmt is the general partner of Deerfield Partners. Deerfield Management is the investment manager of the Funds. Stock options and shares of Common Stock held by Andrew ElBardissi, an employee of Deerfield Management and a director of the Company, are held for the benefit and at the direction of Deerfield Management.

*Percentage beneficial ownership reported herein reflects 33,613,165 shares of Common Stock outstanding, based on 28,113,165 shares of Common Stock outstanding as of March 31, 2021, plus 5,500,000 shares of Common Stock issued in the 2021 Public Offering, as disclosed in the Company’s prospectus on Form 424B4 filed by the Company with the Securities and Exchange Commission on July 15, 2021.

(c) Except as set forth in Items 3, 4 and 6 of this Schedule 13D, no Reporting Person has effected any transactions in the Common Stock during the past 60 days.

Item 6 of the Schedule 13D is hereby amended to add the following:

2021 Lock-up

In connection with the 2021 Public Offering, Deerfield Private Design Fund III and Deerfield Partners entered into lock-up agreements with the underwriters in the 2021 Public Offering (the “2021 Lock-up Agreements”). Pursuant to the Lock-Up Agreements, each Fund agreed with such underwriters, subject to certain exceptions, not to dispose of or enter into hedging arrangements with respect to Common Stock or securities convertible into or exchangeable for shares of Common Stock during the period from the date of the Company’s prospectus for the 2021 Public Offering through the date that is 90 days after the date of such prospectus, except with the prior written consent of certain representatives of the underwriters. The 2021 Lock-up Agreements also prohibit the Funds from exercising any registration rights during such 90-day period. The transfer restrictions contained in the 2021 Lock-Up Agreements do not apply in respect of the transfer of shares acquired in the 2021 Public Offering. The representatives of the underwriters, in their sole discretion, may release shares of Common Stock and other securities subject to the 2021 Lock-up Agreements in whole or in part at any time.

The foregoing description of the 2021 Lock-up Agreements is qualified in its entirety by reference to the full text thereof, the form of which is attached (or incorporated by reference) as Exhibit 6 hereto

Item 7 of the Schedule 13D is hereby amended to add the following:

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: July 21, 2021